[{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"15","companyTruncated":"KVK.Tech \/ Medix"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phentermine Hydrochloride","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute"}]

Find Clinical Drug Pipeline Developments & Deals for Adipex-p (TN)

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the partnership, Medix will gain the exclusive rights to manufacture, distribute, and market Lomaira (Phentermine Hydrochloride) in Mexico. It is indicated for the treatment of obesity.

                          Product Name : Lomaira

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 31, 2024

                          Lead Product(s) : Phentermine Hydrochloride,Inapplicable

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved FDF

                          Sponsor : Medix

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Wake Forest University Health Sciences

                          Country arrow
                          EPSC
                          Not Confirmed

                          Wake Forest University Health Sciences

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Phentermine Hydrochloride,Inapplicable

                          Therapeutic Area : Nutrition and Weight Loss

                          Study Phase : Phase IV

                          Sponsor : Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 04, 2022

                          Lead Product(s) : Phentermine Hydrochloride,Inapplicable

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase IV

                          Sponsor : Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank